Natco Pharma Limited announces the successful delisting of Adcock Ingram Holdings Limited from the Johannesburg Stock Exchange. Natco Pharma has acquired a 35.75% stake in Adcock Ingram in a transaction valued at approximately US$ 226 million (ZAR 4 billion). Adcock Ingram, established in 1891, is a significant pharmaceutical company in South Africa.
Adcock Ingram Delisting Completed
Natco Pharma Limited has finalized the delisting of Adcock Ingram Holdings Limited, a prominent South African pharmaceutical company, from the Johannesburg Stock Exchange (JSE) as of November 11, 2025. The delisting marks the completion of a strategic acquisition where Natco Pharma secured a 35.75% stake.
Strategic Acquisition Details
The transaction, wherein Natco Pharma acquired the 35.75% stake in Adcock Ingram, is valued at approximately US$ 226 million, equivalent to ZAR 4 billion. Adcock Ingram has a long history in South Africa, dating back to 1891, and is known for brands like Panado and Allergex.
Natco’s Future Plans
Natco Pharma aims to utilize Adcock Ingram’s market presence to expand its product offerings in South Africa and beyond. In July 2025, Natco Pharma offered ZAR 75 (US$ 4.36) per share to acquire Adcock Ingram’s minority shareholders, and this proposal was approved in October 2025.
Executive Commentary
Rajeev Nannapaneni, CEO of Natco Pharma, stated that this acquisition is a significant step in their strategic growth plan. He affirmed the commitment to preserving Adcock Ingram’s legacy and enhancing its capabilities to better serve healthcare needs in Africa.
Source: BSE
